Ann: Monepantel Trial Achieves Successful Anti-Cancer Outcome, page-32

PharmAust enters option to license agreement with
Elanco for dog cancer treatment
18 April 2018 – Perth, Australia: PharmAust Limited (ASXAA), a clinical-stage oncology
company, is pleased to announce it has entered into an Option Agreement with Elanco US Inc
(“Elanco”) to develop monepantel as a novel therapy to treat cancer in dogs.
Under this agreement, Elanco will supply PharmAust with GMP-grade monepantel for use in
clinical trials in dogs to determine the anti-cancer potential of the drug. Under the agreement,
PharmAust has granted Elanco an option (“the Elanco Option”) to negotiate for an exclusive,
worldwide royalty bearing commercial licence to use PharmAust’s intellectual property in the
field of treatment of cancer in animals.
PharmAust will manage clinical trials that will assess the efficacy and safety of monepantel in
dogs diagnosed with various cancers. PharmAust will also fund the costs of the clinical trials
and will provide Elanco with regular updates including a final report at the end of the study.
Key features of the Agreement include:
• The parties are Elanco US Inc and Pitney Pharmaceuticals Pty Limited, a wholly owned
subsidiary of PharmAust;
• Elanco will supply PharmAust with GMP-grade monepantel for use in its planned clinical
trials in dogs;
• PharmAust has granted Elanco an option to negotiate for an exclusive, worldwide
royalty bearing commercial licence to use PharmAust’s intellectual property in the field
of treatment of cancer in animals;
• The Elanco Option will continue for a period ending six months after receipt of the final
report for the relevant canine trial that is the subject of the Option Agreement
• Upon Elanco’s exercise of the Elanco Option, the parties shall enter into a negotiation
period not lasting more than six months to agree the terms of the license agreement,
including commercial payments to PharmAust. Should Elanco not proceed to exercise
the option PharmAust will be free to seek alternative commercialisation partners.
PharmAust CEO, Dr Richard Hopkins commented “We are delighted to have entered into this
agreement with Elanco, which helps build a relationship with a potential commercial partner.
The agreement also secures PharmAust with supply of GMP-grade monepantel for use in
clinical trials for dogs with cancer

Not Long,,,, they assisted with trial parameters,,, boxes Ticked ,,